RECEIVED

OCT 1 1 2001

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D. C. 20231.

Date:

#24 FM,

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Jiangchun Xu and Davin C. Dillon

Application No.

09/030,606

Filed

February 25, 1998

For

COMPOUNDS FOR IMMUNODIAGNOSIS OF

PROSTATE CANCER AND METHODS FOR THEIR USE

Examiner

M. Davis

Art Unit

1642

Docket No.

210121.428C3

Date

August 31, 2001

DECLARATION OF DAVIN C. DILLON, PH.D.

Assistant Commissioner of Patents Washington D.C. 20231

The undersigned, Dr. Davin Dillon, Ph.D., hereby declares:

- 1. I am a Scientist and Project Group Leader at Corixa Corporation, the assignee of the subject application, and an inventor of the subject matter disclosed and claimed in the subject patent application. The following experiments were performed under my supervision.
- 2. Several lines of evidence have demonstrated that the identified splice forms of P703P, e.g., SEQ ID NO:172-175 and 177, all exhibit the same prostate-specific expression pattern. The first line of evidence came from the full length cloning efforts to identify P703P. These experiments, using a cDNA library derived from a prostate tumor, resulted in the recovery of all of the identified P703P splice forms, demonstrating that within the same tumor, all splice forms are expressed. Additional evidence revealed that

these splice forms are not expressed in non-prostate normal tissues. This data was generated by employing three types of hybridization-based experiments that used a labeled probe representing a portion of the P703P cDNA common to all splice forms. These experiments included Northern blots, dot blots, and cDNA microarray experiments. In all three types of experiments, detectable hybridization was limited to prostate tumor and normal prostate samples. No other normal tissues yielded specific hybridization. Collectively, this data indicates that the differentially splice P703P mRNAs are expressed in prostate tumors but are not expressed at detectable levels in an extensive panel of non-prostate normal tissues.

3. The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful, false statements, and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Davin C Dillon

Date

D:\NrPortbl\iManage\SHARONS\212101_1.DOC